The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML
暂无分享,去创建一个
Guerry J. Cook | D. Caudell | T. Pardee | David L. Caudell | Howard L. Elford | Timothy S. Pardee | H. Elford
[1] G. Marcucci,et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. , 2012, Blood.
[2] T. Pardee. Overexpression of MN1 Confers Resistance to Chemotherapy, Accelerates Leukemia Onset, and Suppresses p53 and Bim Induction , 2012, PloS one.
[3] Santhosh K. P. Kumar,et al. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells , 2006, British journal of haematology.
[4] C. Mathews. DNA precursor metabolism and genomic stability , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] Asim Khwaja,et al. Acute myeloid leukaemia , 2016, Nature Reviews Disease Primers.
[6] Mansoor M Ahmed,et al. Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. , 2002, Antiviral research.
[7] G. Ehninger,et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. , 2010, Blood.
[8] B. Quesnel,et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.
[9] J. Bigby. Harrison's Principles of Internal Medicine , 1988 .
[10] J. Dipersio,et al. Bone Marrow Stromal Cells Modulate Mouse ENT1 Activity and Protect Leukemia Cells from Cytarabine Induced Apoptosis , 2012, PloS one.
[11] A. Levitzki,et al. Enhanced ROS Production in Oncogenically Transformed Cells Potentiates c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Activation and Sensitization to Genotoxic Stress , 2001, Molecular and Cellular Biology.
[12] C. Mayhew,et al. In Vivo and In Vitro Comparison of the Short‐Term Hematopoietic Toxicity Between Hydroxyurea and Trimidox or Didox, Novel Ribonucleotide Reductase Inhibitors with Potential Anti‐HIV‐1 Activity , 1999, Stem cells.
[13] T. Ishihara,et al. Ribonucleotide Reductase Immunoreactivity in Adenocarcinoma Cells and Malignant or Reactive Mesothelial Cells in Serous Effusions , 2003, Acta Cytologica.
[14] G. Nolan,et al. Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia , 2010, PloS one.
[15] C. Felix,et al. The molecular basis of leukemia. , 2004, Hematology. American Society of Hematology. Education Program.
[16] G. Peters,et al. Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox. , 2001, Experimental hematology.
[17] R. Hills,et al. A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.
[18] T. Naoe,et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia , 2000, European journal of haematology.
[19] M. Minden,et al. Outcomes and quality of care in acute myeloid leukemia over 40 years , 2009, Cancer.
[20] J. Downing,et al. Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.
[21] G. Vercellotti,et al. Robust Vascular Protective Effect of Hydroxamic Acid Derivatives in a Sickle Mouse Model of Inflammation , 2006, Microcirculation.
[22] M. Fukushima,et al. Upregulation of Enzymes Metabolizing 5-Fluorouracil in Colorectal Cancer , 2006, Chemotherapy.
[23] M. Grever,et al. Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia , 2008, Clinical Cancer Research.
[24] H. Kantarjian,et al. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Yujia Dai,et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. , 2007, Blood.
[26] E. Takeda,et al. Role of ribonucleotide reductase in expression in the neoplastic program. , 1981, Life sciences.
[27] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[28] F. Appelbaum,et al. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). , 2001, Experimental hematology.
[29] Tarik Tihan,et al. Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells , 2004, Cancer Chemotherapy and Pharmacology.
[30] G. Wampler,et al. New ribonucleotide reductase inhibitors with antineoplastic activity. , 1979, Cancer research.
[31] J. G. Cory,et al. Inhibitors of Ribonucleoside Diphosphate Reductase Activity , 1989 .
[32] O. Oakley,et al. Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox , 2010, Journal of Inflammation.
[33] K. Döhner,et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. , 2006, Blood.
[34] F. Ferrara,et al. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. , 2004, Haematologica.
[35] D. Kerr,et al. A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor. , 1988, British Journal of Cancer.
[36] Li-ming Wang,et al. Overexpression of catalytic subunit M2 in patients with ovarian cancer. , 2012, Chinese medical journal.
[37] B. Quesnel,et al. p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .
[38] V. Bergdall,et al. Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model. , 2009, Comparative medicine.
[39] Yi Ning,et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.